Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant limertinib ± sintilimab plus chemotherapy in resectable EGFR-mutant NSCLC (Phase II)
ChiCTR2500106897Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of limertinib in EGFR-mutated non-small cell lung cancer (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: pathological complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2500106897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106897.